Clene (NasdaqCM:CLNN) Conference Transcript

Summary of Conference Call Records Clene Inc. (NasdaqCM:CLNN) Industry: Biotechnology / Pharmaceuticals Key Points: - Clene Inc. has been actively engaging with the FDA regarding their clinical data and expanded access protocol for their ALS treatment, CNM-Au8, which is an oral nanocrystal suspension [1][2] - The company reported that their Phase II studies, Healy and Rescue, missed primary endpoints but showed nominally significant results in survival and clinical worsening [2][4] - Clene has provided compassionate use of their drug to over 500 ALS patients, with some individuals receiving treatment for over six years, which is significant given the typical prognosis for ALS patients [3][4] - The Healy study demonstrated a statistically significant benefit in neural filament light levels, which are linked to survival rates, showing an 83% to 84% risk reduction for high neural filament individuals on the drug [5][6] - Clene is preparing to analyze additional data from their expanded access protocol, which could support a new drug application (NDA) filing by the end of the year [9][10] - The company has sufficient cash to navigate upcoming inflection points, including the expected neural filament data and a meeting with the FDA [10][11] Lahontan Gold Corp. (TSXV:LG, OTCQB:LGCXF) Industry: Mining / Gold and Silver Exploration Key Points: - Lahontan Gold Corp. has seen a share price increase of over 1,000% and has experienced significant liquidity in their stock [13] - The company holds four gold and silver exploration properties in Nevada, with their flagship asset, the Santa Fe mine, having 2 million ounces of gold on record [14][15] - Lahontan is currently working on drilling programs to expand their resource estimates and is optimistic about the high-grade gold and silver prices [15][18] - The company is in the process of obtaining permits to drill their entire project, with expectations for full approval by the end of the year [16][17] - Future plans include a new resource estimate and possibly a revised feasibility study, with current gold prices making the project financially attractive [22][23] - Lahontan is focused on low-risk contract mining assumptions and plans to hire key positions as the project progresses [25] Other Important Information: - Clene Inc. is in a critical period with potential for commercialization in 2026 if the NDA is filed successfully [9][10] - Lahontan Gold Corp. is looking to consolidate assets in Nevada and is actively seeking new opportunities while managing operational costs effectively [20][21]